Genetic Signatures Ltd
ASX:GSS
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.405
0.8
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Genetic Signatures Ltd
Genetic Signatures Ltd
Cost of Revenue
Genetic Signatures Ltd
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Genetic Signatures Ltd
ASX:GSS
|
Cost of Revenue
-AU$7.9m
|
CAGR 3-Years
11%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
N/A
|
|
|
Anteotech Ltd
ASX:ADO
|
Cost of Revenue
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Proteomics International Laboratories Ltd
ASX:PIQ
|
Cost of Revenue
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
T
|
Trajan Group Holdings Ltd
ASX:TRJ
|
Cost of Revenue
-AU$94.4m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
N/A
|
|
|
Cryosite Ltd
ASX:CTE
|
Cost of Revenue
-AU$4.6m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-1%
|
|
|
E
|
EZZ Life Science Holdings Ltd
ASX:EZZ
|
Cost of Revenue
-AU$15.5m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
N/A
|
|
Genetic Signatures Ltd
Glance View
Genetic Signatures Ltd. engages in the research and commercialization of identifying individual genetic signatures to identify diseases and disabilities. The company is headquartered in Sydney, New South Wales. The company went IPO on 2015-03-31. The firm is engaged in research and commercialization of identifying individual genetic signatures to aid in the diagnosis of infectious diseases and the sale of associated products into the diagnostic and research marketplaces. The firm is focused on the development and commercialization of its platform technology, 3Base. The Company’s 3Base platform technology provides hospital and pathology laboratories the ability to screen for an array of infectious pathogens, with a degree of specificity, in a rapid throughput (time-to-result) environment. The company also manufactures a Polymerase Chain Reaction (PCR) based products for the detection of infectious diseases under the EasyScreen brand. The Company’s EasyScreen sample processing kits are used to perform 3Base conversion and nucleic acid extraction and purification.
See Also
What is Genetic Signatures Ltd's Cost of Revenue?
Cost of Revenue
-7.9m
AUD
Based on the financial report for Jun 30, 2024, Genetic Signatures Ltd's Cost of Revenue amounts to -7.9m AUD.
What is Genetic Signatures Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-23%
Over the last year, the Cost of Revenue growth was 33%. The average annual Cost of Revenue growth rates for Genetic Signatures Ltd have been 11% over the past three years , -23% over the past five years .
You don't have any saved screeners yet
